Antenatal steroid: Difference between revisions

From Wikipedia, the free encyclopedia
Browse history interactively
← Previous editNext edit →
Content deleted Content added
VisualWikitext
m Adding "update inline" template for Cochrane reference
Updated the Cochrane information and reference.
Line 18: Line 18:
| eMedicine =
| eMedicine =
}}
}}
'''Antenatal steroids''', also known as '''antenatal [[corticosteroid]]s,''' are [[medication]]s administered to pregnant women expecting a [[preterm birth]]. When administered, these steroids accelerate the maturation of the fetus' lungs, which reduces the likelihood of [[infant respiratory distress syndrome]] and infant mortality.<ref name="pmid28321847" /> The effectiveness of this corticosteroid treatment on humans was first demonstrated in 1972 by Sir [[Graham Liggins]] and Ross Howie, during a randomized control trial using betamethasone.<ref name="pmid28321847" /><ref>{{cite journal | vauthors = Liggins GC, Howie RN | title = A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants | journal = Pediatrics | volume = 50 | issue = 4 | pages = 515–25 | date = October 1972 | pmid = 4561295 }}</ref>
'''Antenatal steroids''', also known as '''antenatal [[corticosteroid]]s,''' are [[medication]]s administered to pregnant women expecting a [[preterm birth]]. When administered, these steroids accelerate the maturation of the fetus' lungs, which reduces the likelihood of [[infant respiratory distress syndrome]] and infant mortality.<ref name="pmid28321847" /> The effectiveness of this corticosteroid treatment on humans was first demonstrated in 1972 by Sir [[Graham Liggins]] and Ross Howie, during a randomized control trial using betamethasone.<ref>{{cite journal | vauthors = Liggins GC, Howie RN | title = A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants | journal = Pediatrics | volume = 50 | issue = 4 | pages = 515–25 | date = October 1972 | pmid = 4561295 }}</ref>


==Uses==
==Uses==
Line 25: Line 25:
Antenatal steroids have been shown to reduce the occurrence and mortality of [[hyaline membrane disease|infant respiratory distress syndrome]], a life-threatening condition caused by underdeveloped lungs.<ref name="pmid20348115">{{cite journal | vauthors = Mwansa-Kambafwile J, Cousens S, Hansen T, Lawn JE | title = Antenatal steroids in preterm labour for the prevention of neonatal deaths due to complications of preterm birth | journal = International Journal of Epidemiology | volume = 39 Suppl 1 | issue = Supplement 1 | pages = i122-33 | date = April 2010 | pmid = 20348115 | pmc = 2845868 | doi = 10.1093/ije/dyq029 }}</ref>
Antenatal steroids have been shown to reduce the occurrence and mortality of [[hyaline membrane disease|infant respiratory distress syndrome]], a life-threatening condition caused by underdeveloped lungs.<ref name="pmid20348115">{{cite journal | vauthors = Mwansa-Kambafwile J, Cousens S, Hansen T, Lawn JE | title = Antenatal steroids in preterm labour for the prevention of neonatal deaths due to complications of preterm birth | journal = International Journal of Epidemiology | volume = 39 Suppl 1 | issue = Supplement 1 | pages = i122-33 | date = April 2010 | pmid = 20348115 | pmc = 2845868 | doi = 10.1093/ije/dyq029 }}</ref>


Current evidence suggests that giving antenatal corticosteroids reduces risk of late miscarriages and baby deaths. The baby is also less likely to develop [[Infant respiratory distress syndrome|respiratory distress syndrome]], or require [[mechanical ventilation]].<ref name="pmid28321847">{{cite journal | vauthors = Roberts D, Brown J, Medley N, Dalziel SR | title = Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth | journal = The Cochrane Database of Systematic Reviews | volume = 3 | pages = CD004454 | date = March 2017 | pmid = 28321847 | pmc = 6464568 | doi = 10.1002/14651858.CD004454.pub3 }}</ref>{{Update inline|reason=Updated version https://www.ncbi.nlm.nih.gov/pubmed/33368142|date = February 2021}} They are also less likely to have [[intraventricular hemorrhage]] (bleeding of the brain),<ref name="pmid19544249">{{cite journal | vauthors = Abbasi S, Oxford C, Gerdes J, Sehdev H, Ludmir J | title = Antenatal corticosteroids prior to 24 weeks' gestation and neonatal outcome of extremely low birth weight infants | journal = American Journal of Perinatology | volume = 27 | issue = 1 | pages = 61–6 | date = January 2010 | pmid = 19544249 | doi = 10.1055/s-0029-1223269 }}</ref><ref name="pmid7892866">{{cite journal | vauthors = Ment LR, Oh W, Ehrenkranz RA, Philip AG, Duncan CC, Makuch RW | title = Antenatal steroids, delivery mode, and intraventricular hemorrhage in preterm infants | journal = American Journal of Obstetrics and Gynecology | volume = 172 | issue = 3 | pages = 795–800 | date = March 1995 | pmid = 7892866 | doi = 10.1016/0002-9378(95)90001-2 }}</ref> [[necrotizing enterocolitis]], or systemic infections (infections affecting the whole body) in the first two days of life.<ref name="pmid28321847"/> Steroids do not appear to increase the number of women who develop infection of the fetal membranes ([[chorioamnionitis]]) or of the womb ([[endometritis]]).<ref name="pmid28321847"/> This research evidence is mostly from mid- to high-income countries. However, there is not a lot of research on administering antenatal corticosteroids to women in low-income countries where infections are more common. More research is needed to determine the effects of these steroids on women and babies in low-income countries.<ref name="pmid28321847"/> To address this lack of literature, the WHO is currently conducting a series of multi-national trials in low-resource countries.<ref>{{cite journal | author = WHO ACTION Trials Collaborators | title = The World Health Organization ACTION-I (Antenatal CorTicosteroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, individually randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries | journal = Trials | volume = 20 | issue = 1 | pages = 507 | date = August 2019 | pmid = 31420064 | pmc = 6698040 | doi = 10.1186/s13063-019-3488-z }}</ref>
Current evidence suggests that giving antenatal corticosteroids reduces risk of late miscarriages and baby deaths. The baby is also less likely to develop [[Infant respiratory distress syndrome|respiratory distress syndrome]] or die during of after birth<ref name="pmid28321847">{{cite journal|vauthors=McGoldrick E, Stewart F, Parker R, Dalziel SR|title=Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth|journal=The Cochrane Database of Systematic Reviews|publication-date=December 25, 2020|doi=10.1002/14651858.CD004454.pub4|pmid=33368142}}</ref>. They are also less likely to have [[intraventricular hemorrhage]] (bleeding of the brain)<ref name="pmid19544249">{{cite journal | vauthors = Abbasi S, Oxford C, Gerdes J, Sehdev H, Ludmir J | title = Antenatal corticosteroids prior to 24 weeks' gestation and neonatal outcome of extremely low birth weight infants | journal = American Journal of Perinatology | volume = 27 | issue = 1 | pages = 61–6 | date = January 2010 | pmid = 19544249 | doi = 10.1055/s-0029-1223269 }}</ref><ref name="pmid7892866">{{cite journal | vauthors = Ment LR, Oh W, Ehrenkranz RA, Philip AG, Duncan CC, Makuch RW | title = Antenatal steroids, delivery mode, and intraventricular hemorrhage in preterm infants | journal = American Journal of Obstetrics and Gynecology | volume = 172 | issue = 3 | pages = 795–800 | date = March 1995 | pmid = 7892866 | doi = 10.1016/0002-9378(95)90001-2 }}</ref>, [[necrotizing enterocolitis]], or systemic infections (infections affecting the whole body) in the first two days of life<ref name="pmid28321847" />.
Steroids do not appear to increase the number of women who develop infection of the fetal membranes ([[chorioamnionitis]]) or of the womb ([[endometritis]])<ref name="pmid28321847" />.
The Cochrane review of 2020 about the benefits of corticosteroids when there is a risk of preterm birth states that the "evidence is robust, regardless of resource setting (high, middle or low)"<ref name="pmid28321847" />. The WHO is currently conducting a series of multi-national trials in low-resource countries.<ref>{{cite journal|author=WHO ACTION Trials Collaborators|first=|date=August 2019|title=The World Health Organization ACTION-I (Antenatal Corticosteroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, individually randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries|url=|journal=Trials|volume=20|issue=1|pages=507|doi=10.1186/s13063-019-3488-z|pmc=6698040|pmid=31420064|via=}}</ref>


==== Multiple gestation ====
==== Multiple gestation ====
Further research must be conducted to adequately determine outcomes of antenatal steroid administration for mutifetal pregnancy.<ref name="pmid28321847" /> However, certain national clinical practice guidelines recommend the usage of steroids for preterm birth regardless of multiple gestation.<ref name=":2" />
Further research must be conducted to adequately determine outcomes of antenatal steroid administration for multiple pregnancies.<ref name="pmid28321847" /> However, certain national clinical practice guidelines recommend the usage of steroids for preterm birth regardless of multiple gestation.<ref name=":2" />


=== Preterm premature rupture of membranes ===
=== Preterm premature rupture of membranes ===
Antenatal steroids have also been shown to have definite beneficial effect in treating the condition of [[Premature rupture of membranes|preterm premature rupture of membranes]] (PPROM).<ref name="pmid21508704">{{cite journal|vauthors=Vidaeff AC, Ramin SM|date=June 2011|title=Antenatal corticosteroids after preterm premature rupture of membranes|journal=Clinical Obstetrics and Gynecology|volume=54|issue=2|pages=337–43|doi=10.1097/GRF.0b013e318217d85b|pmid=21508704}}</ref> Similar to its effects on preterm birth, research evidence suggests that the administration of antenatal steroids to patients with PPROM reduces risks of neonatal mortality, intraventricular hemorrhage and respiratory distress syndrome.<ref name="pmid28321847" /><ref>{{Cite journal|last=Harding|first=Jane E.|last2=Pang|first2=Jia-Min|last3=Knight|first3=David B.|last4=Liggins|first4=Graham C.|date=January 2001|title=Do antenatal corticosteroids help in the setting of preterm rupture of membranes?|url=https://doi.org/10.1067/mob.2001.108331|journal=American Journal of Obstetrics and Gynecology|volume=184|issue=2|pages=131–139|doi=10.1067/mob.2001.108331|issn=0002-9378}}</ref>
Antenatal steroids have also been shown to have definite beneficial effect in treating the condition of [[Premature rupture of membranes|preterm premature rupture of membranes]] (PPROM).<ref name="pmid21508704">{{cite journal|vauthors=Vidaeff AC, Ramin SM|date=June 2011|title=Antenatal corticosteroids after preterm premature rupture of membranes|journal=Clinical Obstetrics and Gynecology|volume=54|issue=2|pages=337–43|doi=10.1097/GRF.0b013e318217d85b|pmid=21508704}}</ref> Similar to its effects on preterm birth, research evidence suggests that the administration of antenatal steroids to patients with PPROM reduces risks of neonatal mortality, intraventricular hemorrhage and respiratory distress syndrome.<ref>{{Cite journal|last=Harding|first=Jane E.|last2=Pang|first2=Jia-Min|last3=Knight|first3=David B.|last4=Liggins|first4=Graham C.|date=January 2001|title=Do antenatal corticosteroids help in the setting of preterm rupture of membranes?|url=https://doi.org/10.1067/mob.2001.108331|journal=American Journal of Obstetrics and Gynecology|volume=184|issue=2|pages=131–139|doi=10.1067/mob.2001.108331|issn=0002-9378}}</ref>


== Adverse effects ==
== Adverse effects ==
Line 98: Line 102:


=== Mechanism of action ===
=== Mechanism of action ===
In order to generate improved respiratory outcomes, antenatal steroids act on cells called type II pneumocytes which are located within the [[Pulmonary alveolus|alveoli]] of infant lungs.<ref name=":1">{{Cite journal|last=Vyas|first=J.|last2=Kotecha|first2=S.|date=September 1997|title=Effects of antenatal and postnatal corticosteroids on the preterm lung|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1720703/|journal=Archives of Disease in Childhood Fetal and Neonatal Edition|volume=77|issue=2|pages=F147–F150|issn=1359-2998|pmc=1720703|pmid=9377142}}</ref> Glucocorticoids both increase rates of cell maturation, as well as increase the production of mRNA coding for proteins required for the synthesis of surfactant.<ref name=":1" /> [[Surfactant]] is a phospholipid-rich substance secreted by the lungs in order to increase elasticity and decrease surface tension, consequently generating more efficient rates of ventilation.<ref>{{Cite journal|last=Farrell|first=Philip M.|date=May 1977|title=Fetal lung development and the influence of glucocorticoids on pulmonary surfactant|url=https://doi-org.libaccess.lib.mcmaster.ca/10.1016/0022-4731(77)90248-5|journal=Journal of Steroid Biochemistry|volume=8|issue=5|pages=463–470|doi=10.1016/0022-4731(77)90248-5|issn=0022-4731}}</ref> Additionally, surfactant lines the insides of alveoli in the lungs and as a result, prevents alveoli from collapsing during exhalation.<ref>{{Cite web|last=McMaster Children's Hospital|date=July 2018|title=How surfactant helps your baby's lungs|url=https://www.hamiltonhealthsciences.ca/wp-content/uploads/2019/08/Surfactant-lw.pdf|access-date=28 November 2020|website=Hamilton Health Sciences}}</ref> Since infants born preterm often have immature or incompletely developed lungs, the surfactant coating of the alveoli is similarly insufficient, resulting in poor respiratory outcomes or the development of respiratory distress syndrome.<ref>{{Cite journal|last=Chakraborty|first=Mallinath|last2=Kotecha|first2=Sailesh|date=2013-12-01|title=Pulmonary surfactant in newborn infants and children|url=https://breathe.ersjournals.com/content/9/6/476|journal=Breathe|language=en|volume=9|issue=6|pages=476–488|doi=10.1183/20734735.006513|issn=1810-6838|doi-access=free}}</ref> The antenatal administration of steroids such as betamethasone or dexamethasone increases production of surfactant, and therefore result in better health outcomes for preterm infants.<ref>{{Cite journal|last=Roberts|first=Devender|last2=Brown|first2=Julie|last3=Medley|first3=Nancy|last4=Dalziel|first4=Stuart R|date=2017-03-21|title=Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6464568/|journal=The Cochrane Database of Systematic Reviews|volume=2017|issue=3|doi=10.1002/14651858.CD004454.pub3|issn=1469-493X|pmc=6464568|pmid=28321847}}</ref>{{Update inline|reason=Updated version https://www.ncbi.nlm.nih.gov/pubmed/33368142|date = February 2021}}  
In order to generate improved respiratory outcomes, antenatal steroids act on cells called type II pneumocytes which are located within the [[Pulmonary alveolus|alveoli]] of infant lungs.<ref name=":1">{{Cite journal|last=Vyas|first=J.|last2=Kotecha|first2=S.|date=September 1997|title=Effects of antenatal and postnatal corticosteroids on the preterm lung|url=https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1720703/|journal=Archives of Disease in Childhood Fetal and Neonatal Edition|volume=77|issue=2|pages=F147–F150|issn=1359-2998|pmc=1720703|pmid=9377142}}</ref> Glucocorticoids both increase rates of cell maturation, as well as increase the production of mRNA coding for proteins required for the synthesis of surfactant.<ref name=":1" /> [[Surfactant]] is a phospholipid-rich substance secreted by the lungs in order to increase elasticity and decrease surface tension, consequently generating more efficient rates of ventilation.<ref>{{Cite journal|last=Farrell|first=Philip M.|date=May 1977|title=Fetal lung development and the influence of glucocorticoids on pulmonary surfactant|url=https://doi-org.libaccess.lib.mcmaster.ca/10.1016/0022-4731(77)90248-5|journal=Journal of Steroid Biochemistry|volume=8|issue=5|pages=463–470|doi=10.1016/0022-4731(77)90248-5|issn=0022-4731}}</ref> Additionally, surfactant lines the insides of alveoli in the lungs and as a result, prevents alveoli from collapsing during exhalation.<ref>{{Cite web|last=McMaster Children's Hospital|date=July 2018|title=How surfactant helps your baby's lungs|url=https://www.hamiltonhealthsciences.ca/wp-content/uploads/2019/08/Surfactant-lw.pdf|access-date=28 November 2020|website=Hamilton Health Sciences}}</ref> Since infants born preterm often have immature or incompletely developed lungs, the surfactant coating of the alveoli is similarly insufficient, resulting in poor respiratory outcomes or the development of respiratory distress syndrome.<ref>{{Cite journal|last=Chakraborty|first=Mallinath|last2=Kotecha|first2=Sailesh|date=2013-12-01|title=Pulmonary surfactant in newborn infants and children|url=https://breathe.ersjournals.com/content/9/6/476|journal=Breathe|language=en|volume=9|issue=6|pages=476–488|doi=10.1183/20734735.006513|issn=1810-6838|doi-access=free}}</ref> The antenatal administration of antenatal corticosteroids increases production of surfactant (decreasing the need to use surfactant after birth), and therefore result in better health outcomes for preterm infants<ref name="pmid28321847" />.


== History ==
== History ==

Revision as of 17:32, 5 February 2021

Antenatal steroid
Other namesAntenatal corticosteroids
SpecialtyOB/GYN

Antenatal steroids, also known as antenatal corticosteroids, are medications administered to pregnant women expecting a preterm birth. When administered, these steroids accelerate the maturation of the fetus' lungs, which reduces the likelihood of infant respiratory distress syndrome and infant mortality.[1] The effectiveness of this corticosteroid treatment on humans was first demonstrated in 1972 by Sir Graham Liggins and Ross Howie, during a randomized control trial using betamethasone.[2]

Uses

Preterm birth

Antenatal steroids have been shown to reduce the occurrence and mortality of infant respiratory distress syndrome, a life-threatening condition caused by underdeveloped lungs.[3]

Current evidence suggests that giving antenatal corticosteroids reduces risk of late miscarriages and baby deaths. The baby is also less likely to develop respiratory distress syndrome or die during of after birth[1]. They are also less likely to have intraventricular hemorrhage (bleeding of the brain)[4][5], necrotizing enterocolitis, or systemic infections (infections affecting the whole body) in the first two days of life[1].

Steroids do not appear to increase the number of women who develop infection of the fetal membranes (chorioamnionitis) or of the womb (endometritis)[1].

The Cochrane review of 2020 about the benefits of corticosteroids when there is a risk of preterm birth states that the "evidence is robust, regardless of resource setting (high, middle or low)"[1]. The WHO is currently conducting a series of multi-national trials in low-resource countries.[6]

Multiple gestation

Further research must be conducted to adequately determine outcomes of antenatal steroid administration for multiple pregnancies.[1] However, certain national clinical practice guidelines recommend the usage of steroids for preterm birth regardless of multiple gestation.[7]

Preterm premature rupture of membranes

Antenatal steroids have also been shown to have definite beneficial effect in treating the condition of preterm premature rupture of membranes (PPROM).[8] Similar to its effects on preterm birth, research evidence suggests that the administration of antenatal steroids to patients with PPROM reduces risks of neonatal mortality, intraventricular hemorrhage and respiratory distress syndrome.[9]

Adverse effects

Preliminary research has suggested that the use of antenatal corticosteroids may have adverse long-term effects.[10] In animals, antenatal corticosteroid use has been associated with adverse effects on the cardiometabolic system and inhibited growth of the brain, as well as worsened memory and learning difficulties.[10] While it is not yet certain if human fetuses would experience these same effects, some literature has found that human preterm fetuses treated with antenatal corticosteroids may be at greater risk of developing mental and behavioural disorders during childhood, as these drugs are able to enter the fetus' brain and could affect neurodevelopment.[10] In both humans and animals, research has suggested that repeated doses of antenatal corticosteroids could lead to an increased risk of vision and hearing issues in the long-term.[10]

Contraindications

Contraindications to the administration of antenatal corticosteroids include:[11]

  • Systemic maternal infection
  • Maternal chorioamnionitis

Drugs

Corticosteroids encourage the development of the lungs in a premature fetus before birth,[12] and are administered when the premature fetus is expected to be delivered within 24 to 48 hours. The period of optimal benefit begins 24 hours after administration and lasts 7 days.[13][14] In some parts of the world, antenatal steroids are used at up to 36 weeks of pregnancy.[15] The time between administration of steroids and delivery may alter the effectiveness of the steroids.[16]

National Guidelines Published in English on Antenatal Steroid Administration for Preterm Birth
Country Organization (Year of Publication) Gestational Age Recommendations Other Inclusion Criteria Betamethasone or Dexamethasone
Australia & New Zealand Australian & New Zealand Neonatal Network (2018)[17] < 34 weeks and 6 days Preterm birth anticipated in 1 – 8 days Not specified
Antenatal Corticosteroids Clinical Practice Guidelines

Panel (2015)[18]

≤ 34 weeks and 6 days Preterm birth anticipated in ≥7 days Either Betamethasone or Dexamethasone
Society of Obstetric Medicine of Australia and New Zealand (2014)[19] < 34 weeks - Not specified
Canada Society of Obstetricians & Gynaecologists of Canada (2018)[20] 24 – 34 weeks and 6 days Preterm birth anticipated in ≥7 days Either Betamethasone or Dexamethasone
United Kingdom Royal College of Obstetricians and Gynaecologists (2015)[21] 24 – 33 weeks and 6 days Anticipated preterm birth Not specified
United States of America The American College of Obstetricians and Gynecologists (2020)[7] 24 – 33 weeks and 6 days Preterm birth anticipated within 7 days Betamethasone
International World Health Organization (2015)[22] 24 – 34 weeks Gestational age can be accurately assessed, preterm birth anticipated within 7 days, lack of maternal infection Either Betamethasone or Dexamethasone

Choice of steroid

Common corticosteroids include dexamethasone and betamethasone. Dexamethasone is often recommend over the latter due to its increased efficacy and safety, wide availability, and low cost,[23] while betamethasone is better at preventing the softening of the brain in premature fetuses.[24] Both drugs share certain commonalities, including the ability to traverse the placenta, as well as a very similar molecular structure. In fact, the two steroids are identical save for a single additional methyl group on betamethasone.[25] Although betamethasone has an increased half-life, there is no significant evidence indicating that one might be better than the other.[7] Literature on the subject is limited and inconsistent,[7] with some research indicating that dexamethasone decreases risks of intraventricular hemorrhage,[26] while other studies determined that betamethasone results in improved longer term outcomes.[27]

Mechanism of action

In order to generate improved respiratory outcomes, antenatal steroids act on cells called type II pneumocytes which are located within the alveoli of infant lungs.[28] Glucocorticoids both increase rates of cell maturation, as well as increase the production of mRNA coding for proteins required for the synthesis of surfactant.[28] Surfactant is a phospholipid-rich substance secreted by the lungs in order to increase elasticity and decrease surface tension, consequently generating more efficient rates of ventilation.[29] Additionally, surfactant lines the insides of alveoli in the lungs and as a result, prevents alveoli from collapsing during exhalation.[30] Since infants born preterm often have immature or incompletely developed lungs, the surfactant coating of the alveoli is similarly insufficient, resulting in poor respiratory outcomes or the development of respiratory distress syndrome.[31] The antenatal administration of antenatal corticosteroids increases production of surfactant (decreasing the need to use surfactant after birth), and therefore result in better health outcomes for preterm infants[1].

History

In 1969, Graham Liggins, a medical research scientist, began investigating the effects of dexamethasone administration on the timing of labor in pregnant sheep.[32] Liggins conducted this experiment in the hopes of proving his hypothesis that the fetus, and not the mother, is responsible for inducing labour.[33] Liggins found that dexamethasone caused pregnant sheep to deliver their fetuses prematurely, however, despite the fact that the lamb fetus was extremely premature, it was delivered alive.[33]

With the help of his colleague, pediatrician Ross Howie, Liggins conducted a similar experiment with 282 human women, all of whom were projected to have a preterm delivery.[34] This preliminary trial showed that the administration of corticosteroids, specifically betamethasone, resulted in immediate improvements that were statistically significant, such as:

  • Lowered neonatal mortality rate
  • Reduced incidence of respiratory distress syndrome, but only in fetuses who had
    1. Undergone less than 32 weeks of gestation, and;
    2. Were treated for a minimum 24 hours before they were delivered
  • Reduced incidence of intraventricular cerebral hemorrhage

These findings were first reported in the article A Controlled Trial of Antepartum Glucocorticoid Treatment for Prevention of the Respiratory Distress Syndrome in Premature Infants, published in the journal Pediatrics in 1972.[34] Liggins and Howie’s research proved that antenatal corticosteroids were able to decrease respiratory complications and infant mortality by inducing cellular differentiation, and thus maturation, in the lungs.[33][34] However, these results were not incorporated into clinical practice in the United States until over two decades later.[33]

References

  1. ^ a b c d e f g McGoldrick E, Stewart F, Parker R, Dalziel SR (December 25, 2020). "Antenatal corticosteroids for accelerating fetal lung maturation for women at risk of preterm birth". The Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD004454.pub4. PMID 33368142.
  2. ^ Liggins GC, Howie RN (October 1972). "A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants". Pediatrics. 50 (4): 515–25. PMID 4561295.
  3. ^ Mwansa-Kambafwile J, Cousens S, Hansen T, Lawn JE (April 2010). "Antenatal steroids in preterm labour for the prevention of neonatal deaths due to complications of preterm birth". International Journal of Epidemiology. 39 Suppl 1 (Supplement 1): i122-33. doi:10.1093/ije/dyq029. PMC 2845868. PMID 20348115.
  4. ^ Abbasi S, Oxford C, Gerdes J, Sehdev H, Ludmir J (January 2010). "Antenatal corticosteroids prior to 24 weeks' gestation and neonatal outcome of extremely low birth weight infants". American Journal of Perinatology. 27 (1): 61–6. doi:10.1055/s-0029-1223269. PMID 19544249.
  5. ^ Ment LR, Oh W, Ehrenkranz RA, Philip AG, Duncan CC, Makuch RW (March 1995). "Antenatal steroids, delivery mode, and intraventricular hemorrhage in preterm infants". American Journal of Obstetrics and Gynecology. 172 (3): 795–800. doi:10.1016/0002-9378(95)90001-2. PMID 7892866.
  6. ^ WHO ACTION Trials Collaborators (August 2019). "The World Health Organization ACTION-I (Antenatal Corticosteroids for Improving Outcomes in preterm Newborns) Trial: a multi-country, multi-centre, two-arm, parallel, double-blind, placebo-controlled, individually randomized trial of antenatal corticosteroids for women at risk of imminent birth in the early preterm period in hospitals in low-resource countries". Trials. 20 (1): 507. doi:10.1186/s13063-019-3488-z. PMC 6698040. PMID 31420064. {{cite journal}}: |author= has generic name (help)CS1 maint: unflagged free DOI (link)
  7. ^ a b c d "Antenatal Corticosteroid Therapy for Fetal Maturation". www.acog.org. Retrieved 2020-12-01.
  8. ^ Vidaeff AC, Ramin SM (June 2011). "Antenatal corticosteroids after preterm premature rupture of membranes". Clinical Obstetrics and Gynecology. 54 (2): 337–43. doi:10.1097/GRF.0b013e318217d85b. PMID 21508704.
  9. ^ Harding, Jane E.; Pang, Jia-Min; Knight, David B.; Liggins, Graham C. (January 2001). "Do antenatal corticosteroids help in the setting of preterm rupture of membranes?". American Journal of Obstetrics and Gynecology. 184 (2): 131–139. doi:10.1067/mob.2001.108331. ISSN 0002-9378.
  10. ^ a b c d Asztalos, Elizabeth V.; Murphy, Kellie E.; Matthews, Stephen G. (2020-10-14). "A Growing Dilemma: Antenatal Corticosteroids and Long-Term Consequences". American Journal of Perinatology: s–0040–1718573. doi:10.1055/s-0040-1718573. ISSN 0735-1631.
  11. ^ Miracle, Xavier; Di Renzo, Gian Carlo; Stark, Ann; Fanaroff, Avroy; Carbonell-Estrany, Xavier; Saling (Coordinators of WAPM Premat, Erich (2008-01-01). "Guideline for the use of antenatal corticosteroids for fetal maturation". Journal of Perinatal Medicine. 36 (3). doi:10.1515/JPM.2008.032. ISSN 0300-5577.
  12. ^ Engle WA (February 2008). "Surfactant-replacement therapy for respiratory distress in the preterm and term neonate". Pediatrics. 121 (2): 419–32. doi:10.1542/peds.2007-3283. PMID 18245434.
  13. ^ "Recommendations for Use of Antenatal Corticosteroids". Perinatology.com. Retrieved 6 January 2014.
  14. ^ "Medscape Obstetrics".(subscription required)
  15. ^ "UK National Health Service". Archived from the original on 2012-09-03.
  16. ^ McEvoy C, Schilling D, Spitale P, Peters D, O'Malley J, Durand M (May 2008). "Decreased respiratory compliance in infants less than or equal to 32 weeks' gestation, delivered more than 7 days after antenatal steroid therapy". Pediatrics. 121 (5): e1032-8. doi:10.1542/peds.2007-2608. PMID 18450845.
  17. ^ Chow, SSW, Creighton, P, Chambers, GM, Lui, K. 2020. "Report of the Australian and New Zealand Neonatal Network" 2018. Sydney: ANZNN.
  18. ^ "Antenatal corticosteroids given to women prior to birth to improve fetal, infant, child and adult health: Clinical Practice Guidelines" (PDF). Antenatal Corticosteroid Clinical Practice Guidelines Panel. 2015. Liggins Institute, The University of Auckland, Auckland. New Zealand.
  19. ^ "Guideline for the Management of Hypertensive Disorders of Pregnancy" (PDF). Society of Obstetric Medicine of Australia and New Zealand. 2014.
  20. ^ Skoll, Amanda; Boutin, Amélie; Bujold, Emmanuel; Burrows, Jason; Crane, Joan; Geary, Michael; Jain, Venu; Lacaze-Masmonteil, Thierry; Liauw, Jessica; Mundle, William; Murphy, Kellie (2018). "No. 364-Antenatal Corticosteroid Therapy for Improving Neonatal Outcomes". Journal of Obstetrics and Gynaecology Canada. 40 (9): 1219–1239. doi:10.1016/j.jogc.2018.04.018. ISSN 1701-2163.
  21. ^ "Preterm labour and birth" (PDF). National Institute for Health and Care Excellence. 2015.
  22. ^ "WHO | WHO recommendations on interventions to improve preterm birth outcomes". WHO. Retrieved 2020-12-01.
  23. ^ "Dexamethasone versus betamethasone as an antenatal corticosteroid (ACS)" (PDF). UN Commission / Born Too Soon Care Antenatal Corticosteroids Working Group. August 20, 2013. Archived from the original (PDF) on 6 January 2014. Retrieved 6 January 2014.
  24. ^ "Antenatal Steroid Video". Archived from the original on 2014-01-07. Retrieved 2011-12-27.
  25. ^ Fanaroff, Avroy A.; Hack, Maureen (1999-10-14). "Periventricular Leukomalacia — Prospects for Prevention". New England Journal of Medicine. 341 (16): 1229–1231. doi:10.1056/NEJM199910143411611. ISSN 0028-4793. PMID 10519903.
  26. ^ Brownfoot, Fiona C; Gagliardi, Daniela I; Bain, Emily; Middleton, Philippa; Crowther, Caroline A (2013-08-29). Cochrane Pregnancy and Childbirth Group (ed.). "Different corticosteroids and regimens for accelerating fetal lung maturation for women at risk of preterm birth". Cochrane Database of Systematic Reviews. doi:10.1002/14651858.CD006764.pub3.
  27. ^ Lee, Ben H.; Stoll, Barbara J.; McDonald, Scott A.; Higgins, Rosemary D. (2008-02-01). "Neurodevelopmental Outcomes of Extremely Low Birth Weight Infants Exposed Prenatally to Dexamethasone Versus Betamethasone". Pediatrics. 121 (2): 289–296. doi:10.1542/peds.2007-1103. ISSN 0031-4005. PMID 18245420.
  28. ^ a b Vyas, J.; Kotecha, S. (September 1997). "Effects of antenatal and postnatal corticosteroids on the preterm lung". Archives of Disease in Childhood Fetal and Neonatal Edition. 77 (2): F147–F150. ISSN 1359-2998. PMC 1720703. PMID 9377142.
  29. ^ Farrell, Philip M. (May 1977). "Fetal lung development and the influence of glucocorticoids on pulmonary surfactant". Journal of Steroid Biochemistry. 8 (5): 463–470. doi:10.1016/0022-4731(77)90248-5. ISSN 0022-4731.
  30. ^ McMaster Children's Hospital (July 2018). "How surfactant helps your baby's lungs" (PDF). Hamilton Health Sciences. Retrieved 28 November 2020.
  31. ^ Chakraborty, Mallinath; Kotecha, Sailesh (2013-12-01). "Pulmonary surfactant in newborn infants and children". Breathe. 9 (6): 476–488. doi:10.1183/20734735.006513. ISSN 1810-6838.
  32. ^ Liggins, G. C. (1969-12-01). "PREMATURE DELIVERY OF FOETAL LAMBS INFUSED WITH GLUCOCORTICOIDS". Journal of Endocrinology. 45 (4): 515–523. doi:10.1677/joe.0.0450515. ISSN 0022-0795.
  33. ^ a b c d Norwitz, Errol R; Greenberg, James A (2010). "Beyond Antenatal Corticosteroids: What Did Mont Liggins Teach Us?". Reviews in Obstetrics and Gynecology. 3 (3): 79–80. ISSN 1941-2797. PMC 3046760. PMID 21364857.
  34. ^ a b c Liggins, G. C.; Howie, R. N. (October 1972). "A controlled trial of antepartum glucocorticoid treatment for prevention of the respiratory distress syndrome in premature infants". Pediatrics. 50 (4): 515–525. ISSN 0031-4005. PMID 4561295.

Further reading

Retrieved from "https://en.wikipedia.org/w/index.php?title=Antenatal_steroid&oldid=1005037254"